Clinical Trial Update: A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

View source ↗

Summary

A clinical trial update showing a safety study of zolbetuximab (VYLOY) in South Korea for gastric and gastroesophageal junction cancers, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• VYLOY (ZOLBETUXIMAB)

Snippet

Sponsor: Astellas Pharma Korea, Inc. | Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Status: RECRUITING